P W Flavahan1, T E Lavy, W Wykes. 1. Ophthalmology Department, Southern General Hospital, UK. paulflavahan@doctors.net.uk
Abstract
OBJECTIVE: We report the first case in Scotland of a premature infant treated for retinopathy of prematurity with bevacizumab. METHOD: A case report and a review of the literature are presented. RESULTS: Retinopathy of prematurity is a leading worldwide cause of childhood blindness. Conventional laser treatment results in destruction of the peripheral retina and does not prevent all cases of vision loss, particularly in Zone I disease. We present the case of a baby born at 26(+3) weeks who developed stage 3+ disease located in Zone I of the retina. The patient was treated with bilateral bevacizumab injections and achieved complete resolution of his retinopathy. CONCLUSION: Bevacizumab therapy for the treatment of retinopathy of prematurity is an effective and inexpensive treatment that can readily and quickly be administered by a competent ophthalmologist without the need for specialist equipment.
OBJECTIVE: We report the first case in Scotland of a premature infant treated for retinopathy of prematurity with bevacizumab. METHOD: A case report and a review of the literature are presented. RESULTS:Retinopathy of prematurity is a leading worldwide cause of childhood blindness. Conventional laser treatment results in destruction of the peripheral retina and does not prevent all cases of vision loss, particularly in Zone I disease. We present the case of a baby born at 26(+3) weeks who developed stage 3+ disease located in Zone I of the retina. The patient was treated with bilateral bevacizumab injections and achieved complete resolution of his retinopathy. CONCLUSION:Bevacizumab therapy for the treatment of retinopathy of prematurity is an effective and inexpensive treatment that can readily and quickly be administered by a competent ophthalmologist without the need for specialist equipment.
Entities:
Keywords:
Retinopathy of prematurity; anti-VEGF; bevacizumab
Authors: Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240